Dicarboxylic acids and derivatives

Medchemexpress LLC 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide | 1012054-59-9 | MFCD15528940 | 99.1% | 434.49 g/mol | C24H26N4O4 | 1 ML

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

CUDC-101 is a small-molecule inhibitor that targets histone deacetylases (HDAC) and receptor tyrosine kinases EGFR and HER2. It is intended for research use in studies of signaling pathways, anti-proliferative activity, and preclinical cancer models. The compound is supplied as a high-purity reagent suitable for in vitro experiments.

• Multi-target HDAC, EGFR, and HER2 inhibition
• High purity suitable for research applications
• Available as a ready-to-use 10 mM solution in DMSO (1 mL)
• Confirmed molecular formula and molecular weight for analytical workflows
• Intended for in vitro and preclinical research use

Medchemexpress LLC 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-N-hydroxyheptanamide | 1012054-59-9 | MFCD15528940 | >98.0% | 434.49 g/mol | C24H26N4O4 | 100 MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

CUDC-101 is a small-molecule research compound that concurrently inhibits histone deacetylases (HDACs) and receptor tyrosine kinases EGFR and HER2. It is used in preclinical cancer research to study combined epigenetic and kinase-targeted therapies.

• Potent inhibition of HDAC, EGFR, and HER2 with IC50s of 4.4 nM, 2.4 nM, and 15.7 nM.
• Contains a hydroxamic acid moiety associated with HDAC activity.
• High purity (>98.0%) suitable for research applications.
• Soluble in DMSO at 25 mg/mL (approximately 57.54 mM; may require ultrasonic agitation).
• Molecular formula C24H26N4O4 and molecular weight 434.49 g/mol.

Medchemexpress LLC 7-((4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide | 1012054-59-9 | MFCD15528940 | >98.0% | 434.49 g/mol | C24H26N4O4 | 50 MG

Small and Specialty Supplier Partner
Small and/or specialty supplier based on Federal laws and SBA requirements.
Learn More

CUDC-101 is a small-molecule research inhibitor of histone deacetylases (HDACs), epidermal growth factor receptor (EGFR), and HER2, used in preclinical cancer research to assess antiproliferative and target-specific effects.

• Potent inhibitor of HDAC, EGFR, and HER2 with low-nanomolar activity.
• Demonstrates broad antiproliferative effects across cancer cell lines.
• Supplied as a light yellow to yellow powder for laboratory use.
• High purity suitable for research applications (reported ≥98% by HPLC).
• Available in small-mass packaging for research workflows.
• Molecular weight 434.49 g/mol.